Welcome to our dedicated page for Fulcrum Therapeutics SEC filings (Ticker: FULC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Fulcrum Therapeutics, Inc. (Nasdaq: FULC) SEC filings page on Stock Titan brings together the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Fulcrum is a clinical-stage biopharmaceutical company focused on small-molecule modulation of gene expression for genetically defined rare diseases, with its lead program pociredir in sickle cell disease.
Through this page, readers can access current reports on Form 8-K in which Fulcrum reports material events. Recent 8-K filings describe quarterly financial results, initial and updated data from the Phase 1b PIONEER trial of pociredir in sickle cell disease, and an underwriting agreement for a public offering of common stock and pre-funded warrants. Other 8-Ks cover items such as updated corporate presentations, annual meeting voting results, and stockholder advisory votes on executive compensation.
Fulcrum’s filings also reference its shelf registration statement on Form S-3, under which it has conducted underwritten public offerings, and detail the terms of pre-funded warrants, lock-up agreements, and related underwriting arrangements. As a Nasdaq-listed issuer, Fulcrum files periodic reports and maintains registration of its common stock under Section 12(b) of the Exchange Act.
On Stock Titan, these documents are supplemented with AI-powered summaries that explain the key points of lengthy filings in plain language. Users can quickly see what each 8-K, registration statement, or related exhibit means for topics such as clinical trial updates, capital-raising transactions, and governance matters. Real-time ingestion from EDGAR helps ensure that new Fulcrum filings, including future annual reports on Form 10-K, quarterly reports on Form 10-Q, and insider transaction reports on Form 4 when available, are surfaced promptly with concise AI insights to support further research.
Fulcrum Therapeutics reports Q1 2026 results with a net loss of $18.9 million, slightly wider than the prior-year period. Research and development expense was $14.1 million and general and administrative expense was $8.1 million as the company advances its rare-disease pipeline.
Lead candidate pociredir in sickle cell disease showed encouraging 20 mg PIONEER cohort data: mean absolute HbF rose 12.2% to 19.3%, 58% of patients reached HbF ≥20%, hemoglobin increased 1.1 g/dL, and vaso-occlusive crises fell versus expected events, with a generally well-tolerated safety profile.
Fulcrum ended the quarter with $333.3 million in cash, cash equivalents, and marketable securities and projects this will fund operations into 2029, while it narrows focus on pociredir and core benign hematology programs and exits the CAMP4 bone marrow failure collaboration.
Fulcrum Therapeutics reports Q1 2026 results with a net loss of $18.9 million, slightly wider than the prior-year period. Research and development expense was $14.1 million and general and administrative expense was $8.1 million as the company advances its rare-disease pipeline.
Lead candidate pociredir in sickle cell disease showed encouraging 20 mg PIONEER cohort data: mean absolute HbF rose 12.2% to 19.3%, 58% of patients reached HbF ≥20%, hemoglobin increased 1.1 g/dL, and vaso-occlusive crises fell versus expected events, with a generally well-tolerated safety profile.
Fulcrum ended the quarter with $333.3 million in cash, cash equivalents, and marketable securities and projects this will fund operations into 2029, while it narrows focus on pociredir and core benign hematology programs and exits the CAMP4 bone marrow failure collaboration.
Fulcrum Therapeutics reported first quarter 2026 results and several corporate updates. The company ended the quarter with $333.3 million in cash, cash equivalents, and marketable securities and continues to expect its cash resources will fund operations into 2029. For the quarter ended March 31, 2026, Fulcrum recorded a net loss of $18.9 million, compared with $17.7 million a year earlier, as research and development expenses rose to $14.1 million and general and administrative expenses to $8.1 million.
Fulcrum highlighted positive Phase 1b PIONEER data for its lead sickle cell disease candidate pociredir, including robust fetal hemoglobin induction and improvements in markers of hemolysis and anemia, and plans a potential registration-enabling trial in the second half of 2026. The company also dosed the first patient in a long-term extension trial and maintained that pociredir has been generally well-tolerated with no treatment-related serious adverse events to date.
Strategically, Fulcrum terminated its July 2023 license agreement with CAMP4 Therapeutics covering a Diamond-Blackfan anemia program. Governance changes include appointing Josh Lehrer as an independent Class III director, with a stock option grant for 64,000 shares at $8.08 per share, and the planned retirement of chief financial officer Alan Musso, who will remain until a successor is named and then serve as a consultant to support an orderly transition.
Fulcrum Therapeutics reported first quarter 2026 results and several corporate updates. The company ended the quarter with $333.3 million in cash, cash equivalents, and marketable securities and continues to expect its cash resources will fund operations into 2029. For the quarter ended March 31, 2026, Fulcrum recorded a net loss of $18.9 million, compared with $17.7 million a year earlier, as research and development expenses rose to $14.1 million and general and administrative expenses to $8.1 million.
Fulcrum highlighted positive Phase 1b PIONEER data for its lead sickle cell disease candidate pociredir, including robust fetal hemoglobin induction and improvements in markers of hemolysis and anemia, and plans a potential registration-enabling trial in the second half of 2026. The company also dosed the first patient in a long-term extension trial and maintained that pociredir has been generally well-tolerated with no treatment-related serious adverse events to date.
Strategically, Fulcrum terminated its July 2023 license agreement with CAMP4 Therapeutics covering a Diamond-Blackfan anemia program. Governance changes include appointing Josh Lehrer as an independent Class III director, with a stock option grant for 64,000 shares at $8.08 per share, and the planned retirement of chief financial officer Alan Musso, who will remain until a successor is named and then serve as a consultant to support an orderly transition.
Fulcrum Therapeutics Inc ownership disclosure: The Vanguard Group filed an Amendment No. 2 to a Schedule 13G/A reporting 0 shares beneficially owned and 0% of the common stock as of 03/13/2026. The filing explains an internal realignment that caused certain Vanguard subsidiaries to report separately.
Fulcrum Therapeutics reports another year of heavy investment as it advances pociredir, its lead pill for sickle cell disease, through early clinical development. The company remains unprofitable, posting a $74.9 million net loss in 2025 and an accumulated deficit of $594.3 million as of December 31, 2025.
Pociredir showed encouraging Phase 1b results at the 20 mg dose, with mean fetal hemoglobin rising from 7.1% to 19.3% at Week 12 and markers of hemolysis and anemia improving. Seven of 12 patients reached ≥20% fetal hemoglobin and 58% reported no vaso-occlusive crises during treatment. Fulcrum plans an End-of-Phase meeting with the FDA and aims to start a potential registration-enabling trial in the second half of 2026.
Fulcrum Therapeutics reports another year of heavy investment as it advances pociredir, its lead pill for sickle cell disease, through early clinical development. The company remains unprofitable, posting a $74.9 million net loss in 2025 and an accumulated deficit of $594.3 million as of December 31, 2025.
Pociredir showed encouraging Phase 1b results at the 20 mg dose, with mean fetal hemoglobin rising from 7.1% to 19.3% at Week 12 and markers of hemolysis and anemia improving. Seven of 12 patients reached ≥20% fetal hemoglobin and 58% reported no vaso-occlusive crises during treatment. Fulcrum plans an End-of-Phase meeting with the FDA and aims to start a potential registration-enabling trial in the second half of 2026.
Fulcrum Therapeutics reported a larger full-year 2025 net loss of $74.9 million, compared with $9.7 million in 2024, as it invested in its sickle cell disease program while collaboration revenue fell away. Cash, cash equivalents, and marketable securities rose to $352.3 million as of December 31, 2025, helped by $164.2 million of net proceeds from a December equity offering, giving projected cash runway into 2029.
Clinically, the company announced positive 12-week results from the 20 mg cohort (n=12) of its Phase 1b PIONEER trial of pociredir in sickle cell disease, with mean fetal hemoglobin increasing by 12.2% from 7.1% to 19.3% and improvements in markers of hemolysis and anemia. Pociredir was generally well tolerated with no treatment-related serious adverse events reported at the December 23, 2025 data cutoff. Fulcrum plans an open-label extension study and, pending FDA feedback, aims to start a potential registration-enabling trial in the second half of 2026 while discontinuing its bone marrow failure syndromes program.
Fulcrum Therapeutics reported a larger full-year 2025 net loss of $74.9 million, compared with $9.7 million in 2024, as it invested in its sickle cell disease program while collaboration revenue fell away. Cash, cash equivalents, and marketable securities rose to $352.3 million as of December 31, 2025, helped by $164.2 million of net proceeds from a December equity offering, giving projected cash runway into 2029.
Clinically, the company announced positive 12-week results from the 20 mg cohort (n=12) of its Phase 1b PIONEER trial of pociredir in sickle cell disease, with mean fetal hemoglobin increasing by 12.2% from 7.1% to 19.3% and improvements in markers of hemolysis and anemia. Pociredir was generally well tolerated with no treatment-related serious adverse events reported at the December 23, 2025 data cutoff. Fulcrum plans an open-label extension study and, pending FDA feedback, aims to start a potential registration-enabling trial in the second half of 2026 while discontinuing its bone marrow failure syndromes program.
RA Capital Management and related parties reported a significant stake in Fulcrum Therapeutics, Inc. through an amended Schedule 13G. As of December 31, 2025, the group is deemed to beneficially own 6,649,973 shares of common stock, representing 9.99% of the company.
The RA Capital Healthcare Fund directly holds 6,053,960 shares and pre-funded warrants initially exercisable for up to 8,500,000 shares. A "Beneficial Ownership Blocker" in the warrants limits exercise so that, together with affiliates, RA Capital cannot exceed 9.99% ownership, which currently caps exercisable warrant shares at 596,013.
The filing notes that voting and investment authority over the fund’s holdings has been delegated to RA Capital and that the securities were not acquired to change or influence control of Fulcrum Therapeutics.
Fulcrum Therapeutics, Inc. director Robert J. Gould sold 15,000 shares of common stock on January 2, 2026 under a Rule 10b5-1 trading plan adopted on August 1, 2025. The weighted average sale price was $10.8726, with individual trades between $10.60 and $11.33.
After these transactions, Gould beneficially owned 469,864 shares of Fulcrum Therapeutics common stock. This amended report updates the previously reported weighted average sale price from $11.8726 to $10.8726.
Fulcrum Therapeutics reported an equity award to its Chief Financial Officer, Alan Musso. On February 2, 2026, he received a stock option to purchase 170,000 shares of common stock at an exercise price of $10.72 per share. Following this grant, he beneficially owns 170,000 derivative securities tied to company stock.
The option is scheduled to vest in equal quarterly installments over four years, beginning on January 1, 2026, and each vesting date requires his continued service. This type of award aligns the CFO’s potential compensation with future stock performance over a multi‑year period.
Fulcrum Therapeutics’ Chief Legal Officer receives new stock option grant. On February 2, 2026, Curtis Gale Oltmans was granted options to purchase 170,000 shares of Fulcrum Therapeutics common stock at an exercise price of $10.72 per share, expiring February 1, 2036.
The options are scheduled to vest in equal quarterly installments over four years, beginning on a vesting commencement date of January 1, 2026, and require his continued service with the company on each vesting date.
Fulcrum Therapeutics director Robert J. Gould reported an automatic stock sale under a pre-set trading plan. On 02/02/2026, he sold 15,000 shares of Fulcrum Therapeutics common stock at a weighted average price of $10.7238 per share, coded as an open market sale.
The transaction was executed pursuant to a Rule 10b5-1 trading plan that he adopted on August 1, 2025, which allows pre-arranged trades. After this sale, Gould beneficially owned 454,864 shares of Fulcrum Therapeutics common stock in direct ownership.